WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES - Kristina Ilieva; Karin Landgraf; Rainer Boxhammer; Stefan Steidl; Donna Flesher (Kidney International Reports)